Telemus Capital LLC trimmed its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 43.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,041 shares of the biopharmaceutical company’s stock after selling 3,909 shares during the period. Telemus Capital LLC owned about 308.00% of Bristol-Myers Squibb worth $321,000 at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in shares of Bristol-Myers Squibb by 0.3% during the second quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock valued at $6,611,829,000 after acquiring an additional 333,685 shares during the period. BlackRock Inc. boosted its holdings in shares of Bristol-Myers Squibb by 2.4% during the second quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock valued at $5,541,612,000 after acquiring an additional 2,367,864 shares during the period. Dodge & Cox boosted its holdings in shares of Bristol-Myers Squibb by 1.6% during the second quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock valued at $1,648,168,000 after acquiring an additional 459,271 shares during the period. Northern Trust Corp lifted its holdings in Bristol-Myers Squibb by 3.9% in the second quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock worth $1,339,612,000 after purchasing an additional 910,496 shares during the period. Finally, Jennison Associates LLC lifted its holdings in Bristol-Myers Squibb by 5.4% in the second quarter. Jennison Associates LLC now owns 23,118,789 shares of the biopharmaceutical company’s stock worth $1,288,179,000 after purchasing an additional 1,184,652 shares during the period. Institutional investors and hedge funds own 69.74% of the company’s stock.
Bristol-Myers Squibb Co (NYSE:BMY) opened at $59.92 on Wednesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. The company has a market capitalization of $98,070.00, a price-to-earnings ratio of 23.59, a P/E/G ratio of 2.30 and a beta of 1.18. Bristol-Myers Squibb Co has a 12 month low of $46.01 and a 12 month high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The firm had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same quarter in the previous year, the company posted $0.77 earnings per share. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. research analysts predict that Bristol-Myers Squibb Co will post 2.99 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be paid a dividend of $0.40 per share. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a yield of 2.67%. The ex-dividend date of this dividend is Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio is currently 62.99%.
In related news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the transaction, the executive vice president now owns 9,251 shares in the company, valued at $585,033.24. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the transaction, the executive vice president now owns 584,373 shares in the company, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.
BMY has been the subject of a number of research analyst reports. Barclays upped their price target on shares of Bristol-Myers Squibb from $58.00 to $65.00 and gave the company an “equal weight” rating in a report on Friday, October 13th. Jefferies Group downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price target for the company. in a report on Monday, October 16th. BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a report on Thursday, October 12th. Leerink Swann boosted their price objective on Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a report on Monday, October 23rd. Finally, Citigroup upped their target price on Bristol-Myers Squibb to $72.00 and gave the company a “buy” rating in a report on Wednesday, October 18th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $65.11.
TRADEMARK VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/17/telemus-capital-llc-has-321000-holdings-in-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.